The following is a summary of “Effective and durable repigmentation for stable vitiligo: A randomized within-subject ...

I explained last Monday that there are, in general, two types of stem cell therapies. I started with the autologous stem cell ...

Humacyte stock has dropped 46% since July, mainly due to FDA review delays. Check out why I downgraded HUMA stock from "buy" ...

The director of solid tumor therapy at Stanford Medicine describes how cellular therapies are transforming cancer care.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding ...

This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Benchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares.

In February 2024, the FDA approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil and leucovorin for the ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

Vittoria Biotherapeutics doses first patient in phase 1 clinical trial of VIPER-101: Philadelphia Monday, December 23, 2024, 13:00 Hrs [IST] Vittoria Biotherapeutics, Inc, a clini ...

Other products in burn and wound care include autologous skin suspension products such as RECELL by Avita. A recent academic article in the Journal of Burn Care & Research concluded that using RECELL ...